Avanir Pharmaceuticals (AVNR) Reports In-Line Q4 Loss of 9c/Share

December 12, 2012 4:02 PM EST Send to a Friend
Avanir Pharmaceuticals (NASDAQ: AVNR) reported Q4 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $13.5 million versus the consensus estimate of $12.9 million.

For earnings history and earnings-related data on Avanir Pharmaceuticals (AVNR) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings

Add Your Comment